<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Omalizumab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Omalizumab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Omalizumab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Omalizumab</b>, sold under the trade name <b>Xolair</b>, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria.</p>



<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Omalizumab</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Humanized (from mouse)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>IgE Fc region</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td>oh-ma-liz'-oom-ab<span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Xolair</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/omalizumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/omalizumab.html'" tppabs="https://www.drugs.com/monograph/omalizumab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Omalizumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Omalizumab'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Omalizumab" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">

<ul><li>B</li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>subcutaneous injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>R03DX05<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=R03DX05  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=R03DX05'" tppabs="https://www.whocc.no/atc_ddd_index/?code=R03DX05" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>26 days</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=242138-07-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=242138-07-4'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=242138-07-4" class="external text external">242138-07-4</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00043  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00043'" tppabs="https://www.drugbank.ca/drugs/DB00043" class="external text external">DB00043</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=2P471X1Z11  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=2P471X1Z11'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=2P471X1Z11" class="external text external">2P471X1Z11</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201589  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201589'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201589" class="external text external">ChEMBL1201589</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6450</sub><span>H</span><sub>9916</sub><span>N</span><sub>1714</sub><span>O</span><sub>2023</sub><span>S</span><sub>38</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">145<span style="margin-left:.25em;">058</span>.53</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458283563&page2=Omalizumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458283563&page2=Omalizumab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458283563&page2=Omalizumab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.<span class="mw-ref" id="cite_ref-pmid11704611_1-0"><a href="#cite_note-pmid11704611-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.<span class="mw-ref" id="cite_ref-pmid17383539_2-0"><a href="#cite_note-pmid17383539-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Allergic_asthma">Allergic asthma</h3></summary>
    
<p>Omalizumab is used to treat people with severe, persistent allergic asthma, uncontrollable with oral or injectable corticosteroids.<span class="mw-ref" id="cite_ref-AFP05_3-0"><a href="#cite_note-AFP05-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Those patients have already failed step I to step IV treatments and are in step V of treatment. Such a treatment scheme is consistent with the widely adopted guidelines for the management and prevention of asthma, issued by Global Initiative of Asthma (GINA), which was a medical guidelines organization launched in 1993 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and the World Health Organization.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p> 


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Chronic_spontaneous_urticaria">Chronic spontaneous urticaria</h3></summary>
    
<p>Omalizumab is indicated for chronic spontaneous urticaria  in adults and adolescents (&gt;12 years old) poorly responsive to H1-antihistamine therapy<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span>. When administered subcutaneously once every four weeks, Omalizumab has been shown to significantly decrease itch severity and hive count<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span>.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000.<span class="mw-ref" id="cite_ref-AFP05_3-1"><a href="#cite_note-AFP05-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Limited studies are available to confirm whether omalizumab increases the risk of developing cardiovascular (CV) or cerebrovascular disease (CBV). Cohort and randomised controlled studies have shown that the risk of developing CV/CBV disease is around 20-32% higher in patients taking omalizumab compared to those not taking omalizumab[46,47]. Additional multi-national, longitudinal studies with increased subject numbers are required to provide further clarification into the relationship and clinical significance between omalizumab and CV/CBV disease[46,47]. Due to the severity of CV/CBVs side effects, clinicians and health care providers should continue to remain vigilant and monitor side effects when treating patients with omalizumab. </p>

<p>IgE may play an important role in the immune system's recognition of cancer cells.<span class="mw-ref" id="cite_ref-pmid12672069_11-0"><a href="#cite_note-pmid12672069-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Therefore, indiscriminate blocking of IgE-receptor interaction with omalizumab may have unforeseen risks. The data pooled in 2003 from the earlier phase I to phase III clinical trials showed a numeric imbalance in malignancies arising in omalizumab recipients (0.5%) compared with control subjects (0.2%).<span class="mw-ref" id="cite_ref-AFP05_3-2"><a href="#cite_note-AFP05-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> A 2012 study found that a causal link with cancer was unlikely.<span class="mw-ref" id="cite_ref-pmid22365654_12-0"><a href="#cite_note-pmid22365654-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>The rationale for designing the anti-IgE therapeutic antibodies and the pharmacological mechanisms of anti-IgE therapy have been summarized in review articles by the inventor of the anti-IgE therapy, Tse Wen Chang, and his colleagues.<span class="mw-ref" id="cite_ref-pmid17383539_2-1"><a href="#cite_note-pmid17383539-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-pmid10657120_13-0"><a href="#cite_note-pmid10657120-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-pmid16750976_14-0"><a href="#cite_note-pmid16750976-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<p>Perhaps the most dramatic effect, which was not foreseen at the time when the anti-IgE therapy was designed and which was discovered during the clinical trials, is that as the free IgE in patients is depleted by omalizumab, the FcεRI receptors on basophils, mast cells, and dendritic cells are gradually down-regulated with somewhat different kinetics, rendering those cells much less sensitive to the stimulation by allergens.<span class="mw-ref" id="cite_ref-pmid9013989_15-0"><a href="#cite_note-pmid9013989-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-pmid14657874_16-0"><a href="#cite_note-pmid14657874-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-pmid15748543_17-0"><a href="#cite_note-pmid15748543-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span>  Thus, in this regard, therapeutic anti-IgE antibodies represent a new class of potent mast cell stabilizers,<span class="mw-ref" id="cite_ref-pmid16750976_14-1"><a href="#cite_note-pmid16750976-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> providing the fundamental mechanism for omalizumab's effects on various allergic and non-allergic diseases involving mast cell degranulation. Many investigators have identified or elucidated a host of pharmacological effects, which help bring down the inflammatory status in the omalizumab-treated patients.<span class="mw-ref" id="cite_ref-pmid15836747_18-0"><a href="#cite_note-pmid15836747-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-pmid15753888_19-0"><a href="#cite_note-pmid15753888-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-pmid19839977_20-0"><a href="#cite_note-pmid19839977-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="IgE_in_allergic_diseases">IgE in allergic diseases</h3></summary>
    
<p>In conjunction with achieving the practical goal to investigate the applicability of the anti-IgE therapy as a potential treatment for allergic diseases, the many corporate-sponsored clinical trials of TNX-901 and omalizumab on asthma, allergic rhinitis, peanut allergy, chronic idiopathic urticaria, atopic dermatitis, and other allergic diseases, have helped define the role of IgE in the pathogenesis of these prevalent allergic diseases. For example, the clinical trial results of omalizumab on asthma have unambiguously settled the long debate whether IgE plays a central role in the pathogenesis of asthma.<span class="mw-ref" id="cite_ref-pmid15753888_19-1"><a href="#cite_note-pmid15753888-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span>
Numerous investigator-initiated case studies or small-scale pilot studies of omalizumab have been performed on various allergic diseases and several non-allergic diseases, especially inflammatory skin diseases. These diseases include atopic dermatitis, various subtypes of physical urticaria (solar, cold-induced, local heat-induced, or delayed pressure-induced), and a spectrum of relatively less prevalent allergic or non-allergic diseases or conditions, such as allergic bronchopulmonary aspergillosis,<span class="mw-ref" id="cite_ref-pmid17329558_21-0"><a href="#cite_note-pmid17329558-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> cutaneous or systemic mastocytosis, bee venom sensitivity (anaphylaxis),<span class="mw-ref" id="cite_ref-pmid20568389_22-0"><a href="#cite_note-pmid20568389-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> idiopathic anaphylaxis, eosinophil-associated gastrointestinal disorder, bullous pemphigoid,<span class="mw-ref" id="cite_ref-pmid19152970_23-0"><a href="#cite_note-pmid19152970-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> interstitial cystitis,<span class="mw-ref" id="cite_ref-pmid16771742_24-0"><a href="#cite_note-pmid16771742-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> nasal polyps, and idiopathic angiodema,.<span class="mw-ref" id="cite_ref-pmid17931567_25-0"><a href="#cite_note-pmid17931567-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Roles_in_non-allergic_diseases">Roles in non-allergic diseases</h3></summary>
    
<p>Several groups have reported clinical trial results that omalizumab may be effective in patients with non-allergic asthma.<span class="mw-ref" id="cite_ref-pmid23350994_26-0"><a href="#cite_note-pmid23350994-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> This seems to be contrary to the general understanding of the pharmacological mechanisms of the anti-IgE therapy discussed above.<span class="mw-ref" id="cite_ref-pmid23709757_27-0"><a href="#cite_note-pmid23709757-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Furthermore, among the diseases in which omalizumab has been studied for efficacy and safety, some are not allergic diseases, because hypersensitivity reactions toward external antigens is not involved. For example, a portion of the cases of chronic idiopathic urticaria<span class="mw-ref" id="cite_ref-pmid23432142_28-0"><a href="#cite_note-pmid23432142-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-pmid23810097_29-0"><a href="#cite_note-pmid23810097-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> and all cases of bullous pemphigoid<span class="mw-ref" id="cite_ref-pmid19152970_23-1"><a href="#cite_note-pmid19152970-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> are clearly autoimmune diseases. For the remaining cases of chronic idiopathic urticaria and those of the different subtypes of physical urticaria, the internal abnormalities leading to the disease manifestation have not been identified. Notwithstanding these developments, it is apparent that many of those diseases involve inflammatory reactions in the skin and the activation of mast cells. An increasing series of papers have shown that IgE potentiates the activities of mast cells<span class="mw-ref" id="cite_ref-pmid21713650_30-0"><a href="#cite_note-pmid21713650-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> and omalizumab can function as a mast cell-stabilizing agent,<span class="mw-ref" id="cite_ref-pmid16750976_14-2"><a href="#cite_note-pmid16750976-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> rendering these inflammatory cells to be less active.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry_and_formulations">Chemistry and formulations</h2></summary>
    
<p>Omalizumab is a glycosylated IgG1 monoclonal antibody produced by cells of an adapted Chinese hamster ovary (CHO) cell line.<span class="mw-ref" id="cite_ref-pmid17383539_2-2"><a href="#cite_note-pmid17383539-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> The antibody molecules are secreted by the host cells in a cell culture process employing large-scale bioreactors. At the end of culturing, the IgG contained in the medium is purified by an affinity-column using Protein A as the adsorbent, followed by chromatography steps, and finally concentrated by UF/DF (paired ultra filtration/depth filtration).  Omalizumab is manufactured at the Novartis' Huningue manufacturing site (France)<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> through a partnership agreement with Genentech.</p>

<p>Omalizumab was for several years provided only in a dry powder formulation, which requires the reconstitution with a prepacked solvent with the help of a shaker at the treating clinician’s office before injection. A prefilled syringe liquid formulation has become available in many countries.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p></p>
<p>Tanox, a biopharmaceutical company based in Houston, Texas, started the anti-IgE program, created antibody drug candidates, and filed its first patent application on the anti-IgE therapeutic approach in 1987.<span class="mw-ref" id="cite_ref-The_Scientist_33-0"><a href="#cite_note-The_Scientist-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> In the next year, the company converted one candidate antibody to a chimeric antibody (which was later named CGP51901 and further developed into a humanized antibody, TNX-901 or talizumab). The anti-IgE therapeutic concept was not well received in the early period of the program. In order to seek  funding for the anti-IgE program, the two scientist founders of Tanox, Nancy T. Chang and Tse Wen Chang, visited about 25 pharmaceutical and larger biotech companies in the U.S., Canada, Europe, Japan, and other countries to discuss collaboration throughout 1989. Representatives of Ciba-Geigy (which merged with Sandoz to form Novartis in 1996) thought the anti-IgE program scientifically interesting and executives from Tanox and Ciba-Geigy signed a collaborative agreement in 1990 to develop the anti-IgE program.<span class="mw-ref" id="cite_ref-The_Scientist_33-1"><a href="#cite_note-The_Scientist-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>

<p>In 1991, after several rounds of pre-IND ("investigational new drug") meetings with officials/scientists of the FDA, the FDA finally gave a nod for CGP51901 to be tested in human subjects. This approval of IND for an anti-IgE antibody for the first time was regarded a brave demonstration of professionalism for both the FDA officials and the Tanox/Ciba-Geigy team. The scientists participating in the pre-IND discussion comprehended that an ordinary anti-IgE antibody (i.e., one without the set of binding specificity of CGP51901) would invariably activate mast cells and basophils and cause anaphylactic shocks and probably deaths among injected persons. Notwithstanding this concern, they came to the same view that based on the presented scientific data, CGP51901 should have an absolutely required clean distinction from an ordinary anti-IgE antibody in this regard.<span class="mw-ref" id="cite_ref-pmid1369991_35-0"><a href="#cite_note-pmid1369991-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span><span class="mw-ref" id="cite_ref-pmid8362344_36-0"><a href="#cite_note-pmid8362344-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> In 1991-1993, researchers from Ciba-Geigy and Tanox and a leading clinical research group (headed by Stephen Holgate) in the asthma/allergy field ran a successful Phase I human clinical trial of CGP51901 in Southampton, England and showed that the tested antibody is safe.<span class="mw-ref" id="cite_ref-pmid9062345_37-0"><a href="#cite_note-pmid9062345-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> In 1994-1995, the Tanox/Ciba-Geigy team conducted a Phase II trial of CGP51901 in patients with severe allergic rhinitis in Texas and showed that CGP51901 is safe and efficacious in relieving allergic symptoms.<span class="mw-ref" id="cite_ref-pmid9433396_38-0"><a href="#cite_note-pmid9433396-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<p>While the Tanox/Ciba-Geigy anti-IgE program was gaining momentum, Genentech announced in 1993 that it also had an anti-IgE program for developing antibody therapeutics for asthma and other allergic diseases. Scientists in Genentech had made a mouse anti-IgE monoclonal antibody with the binding specificity similar to that of CGP51901 and subsequently humanized the antibody (the antibody was later named "omalizumab").<span class="mw-ref" id="cite_ref-pmid8360482_39-0"><a href="#cite_note-pmid8360482-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> This caused great concerns in Tanox, because it had disclosed its anti-IgE technology and sent its anti-IgE antibody candidate, which was to become CGP51901 and TNX-901, to Genentech in 1989 for the latter to evaluate for the purpose of considering establishing a corporate partnership.<span class="mw-ref" id="cite_ref-Drug_War_40-0"><a href="#cite_note-Drug_War-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span> Having failed to receive reconciliation from Genentech, Tanox filed a lawsuit against Genentech for trade secret violation.<span class="mw-ref" id="cite_ref-Drug_War_40-1"><a href="#cite_note-Drug_War-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span> Coincidentally, Tanox started to receive major patents for its anti-IgE invention from the European Union and from the U.S. in 1995.<span class="mw-ref" id="cite_ref-anti-IgE_patents_41-0"><a href="#cite_note-anti-IgE_patents-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> After a 3-year legal entanglement, Genentech and Tanox settled their lawsuits out-of-court and Tanox, Novartis, and Genentech formed a tripartite partnership to jointly develop the anti-IgE program in 1996.<span class="mw-ref" id="cite_ref-Tripartite_Agreement_42-0"><a href="#cite_note-Tripartite_Agreement-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> Omalizumab became the drug of choice for further development, because it had a better developed manufacturing process than TNX-901.<span class="mw-ref" id="cite_ref-Tripartite_Agreement_42-1"><a href="#cite_note-Tripartite_Agreement-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> A large number of corporate-sponsored clinical trials and physician-initiated case series studies on omalizumab have been planned and performed since 1996 and a large number of research reports, especially those of clinical trial results, have been published since around 2000, as described and referenced in other sections of this article.
In 2007, Genetech bought Tanox at $20/share for approximately $900 Million.<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    
<p>Due to the high cost of an omalizumab, and the concern over long-term safety, treatment is not yet very common, especially in developing countries. Another barrier to wide use is its injectable dosage form. In August 2010, the National Institute for Clinical Excellence (NICE) in the United Kingdom ruled that omalizumab should not be prescribed on the National Health Service (NHS) to children under 12.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> NICE concluded that the high costs of the compound, over £250 per vial, did not represent a sufficiently high increase in quality of life. However, on March 7, 2013, NICE issued “final draft guidance” about the allowance of omalizumab. It recommended the medication as an option for treating severe, persistent allergic asthma in adults, adolescents and children following additional analyses and submission of a patient access scheme (PAS) by Novartis, the manufacturer.<span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></p>

<p>In August 2013, a researcher at Leiden University Medical Center responsible for the TIGER trial was fired for unrelated research fraud. The TIGER trial was halted as a result.<span class="mw-ref" id="cite_ref-fraud_47-0"><a href="#cite_note-fraud-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></p>

<p>In the United States it costs about $US540 to $2,700 per month as of 2005.<span class="mw-ref" id="cite_ref-48"><a href="#cite_note-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Citations">Citations</h3></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-pmid11704611-1"> <span id="mw-reference-text-cite_note-pmid11704611-1" class="mw-reference-text"><cite id="CITEREFSchulman_ES2001" class="citation journal cs1">Schulman ES (October 2001). "Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders". <i>Am J Respir Crit Care Med</i>. <b>164</b> (8 Pt 2): S6–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1164%2Fajrccm.164.supplement_1.2103025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1164%2Fajrccm.164.supplement_1.2103025'" tppabs="https://doi.org/10.1164%2Fajrccm.164.supplement_1.2103025" class="external text external">10.1164/ajrccm.164.supplement_1.2103025</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11704611  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11704611'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11704611" class="external text external">11704611</a>.</cite></span></li><li id="cite_note-pmid17383539-2"> <span id="mw-reference-text-cite_note-pmid17383539-2" class="mw-reference-text"><cite id="CITEREFChangWuHsuHung2007" class="citation book cs1">Chang TW, Wu PC, Hsu CL, Hung AF (2007). <i>Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases</i>. <i>Adv. Immunol</i>. Advances in Immunology. <b>93</b>. pp.<span>&nbsp;</span>63–119. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0065-2776%2806%2993002-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0065-2776%2806%2993002-8'" tppabs="https://doi.org/10.1016%2FS0065-2776%2806%2993002-8" class="external text external">10.1016/S0065-2776(06)93002-8</a>. ISBN<span>&nbsp;</span><bdi>9780123737076</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17383539  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17383539'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17383539" class="external text external">17383539</a>.</cite></span></li><li id="cite_note-AFP05-3"> <span id="mw-reference-text-cite_note-AFP05-3" class="mw-reference-text"><cite id="CITEREFDavydov_L2005" class="citation journal cs1">Davydov L (January 2005). "Omalizumab (Xolair) for treatment of asthma". <i>Am Fam Physician</i>. <b>71</b> (2): 341–2. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15686303  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15686303'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15686303" class="external text external">15686303</a>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text">Pocket guide for asthma management and prevention. Global Initiatives for Asthma. 2013. <cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20130521081528/http://www.ginasthma.org/documents/1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130521081528/http://www.ginasthma.org/documents/1'" tppabs="https://web.archive.org/web/20130521081528/http://www.ginasthma.org/documents/1" class="external text external">"Archived copy"</a>. Archived from <a href="javascript:if(confirm('http://www.ginasthma.org/documents/1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ginasthma.org/documents/1'" tppabs="http://www.ginasthma.org/documents/1" class="external text external">the original</a> on 2013-05-21<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-07-07</span></span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFUrgertElzenKnulstFedorowicz2015" class="citation journal cs1">Urgert, M.C.; Elzen, M.T.; Knulst, A.C.; Fedorowicz, Z.; Zuuren, E.J. (22 July 2015). "Omalizumab in patients with chronic spontaneous urticaria: a systematic review and assessment". <i>British Journal of Dermatology</i>. <b>173</b> (2): 404–415. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fbjd.13845  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fbjd.13845'" tppabs="https://doi.org/10.1111%2Fbjd.13845" class="external text external">10.1111/bjd.13845</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25891046  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25891046'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25891046" class="external text external">25891046</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite id="CITEREFBernsteinKavatiTharpOrtiz2018" class="citation journal cs1">Bernstein, Jonathan A.; Kavati, Abhishek; Tharp, Michael D.; Ortiz, Benjamin; MacDonald, Karen; Denhaerynck, Kris; Abraham, Ivo (16 February 2018). <a href="javascript:if(confirm('https://doi.org/10.1080/14712598.2018.1438406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080/14712598.2018.1438406'" tppabs="https://doi.org/10.1080/14712598.2018.1438406" class="external text external">"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence"</a>. <i>Expert Opinion on Biological Therapy</i>. <b>18</b> (4): 425–448. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1080%2F14712598.2018.1438406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F14712598.2018.1438406'" tppabs="https://doi.org/10.1080%2F14712598.2018.1438406" class="external text external">10.1080/14712598.2018.1438406</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29431518  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29431518'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29431518" class="external text external">29431518</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation journal cs1">Urgert, M.C.; Elzen, M.T.; Knulst, A.C.; Fedorowicz, Z.; Zuuren, E.J. (22 July 2015). "Omalizumab in patients with chronic spontaneous urticaria: a systematic review and assessment". <i>British Journal of Dermatology</i>. <b>173</b> (2): 404–415. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fbjd.13845  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fbjd.13845'" tppabs="https://doi.org/10.1111%2Fbjd.13845" class="external text external">10.1111/bjd.13845</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25891046  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25891046'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25891046" class="external text external">25891046</a>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite class="citation journal cs1">Bernstein, Jonathan A.; Kavati, Abhishek; Tharp, Michael D.; Ortiz, Benjamin; MacDonald, Karen; Denhaerynck, Kris; Abraham, Ivo (16 February 2018). <a href="javascript:if(confirm('https://doi.org/10.1080/14712598.2018.1438406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080/14712598.2018.1438406'" tppabs="https://doi.org/10.1080/14712598.2018.1438406" class="external text external">"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence"</a>. <i>Expert Opinion on Biological Therapy</i>. <b>18</b> (4): 425–448. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1080%2F14712598.2018.1438406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F14712598.2018.1438406'" tppabs="https://doi.org/10.1080%2F14712598.2018.1438406" class="external text external">10.1080/14712598.2018.1438406</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29431518  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29431518'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29431518" class="external text external">29431518</a>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFZhaoJiYuMeng2016" class="citation journal cs1">Zhao, Zuo-Tao; Ji, Chun-Mei; Yu, Wen-Jun; Meng, Ling; Hawro, Tomasz; Wei, Ji-Fu; Maurer, Marcus (June 2016). <a href="javascript:if(confirm('https://doi.org/10.1016/j.jaci.2015.12.1342  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.jaci.2015.12.1342'" tppabs="https://doi.org/10.1016/j.jaci.2015.12.1342" class="external text external">"Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials"</a>. <i>Journal of Allergy and Clinical Immunology</i>. <b>137</b> (6): 1742–1750.e4. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2015.12.1342  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2015.12.1342'" tppabs="https://doi.org/10.1016%2Fj.jaci.2015.12.1342" class="external text external">10.1016/j.jaci.2015.12.1342</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27040372  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27040372'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27040372" class="external text external">27040372</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFFanta_CH2009" class="citation journal cs1">Fanta CH (March 2009). "Asthma". <i>N. Engl. J. Med</i>. <b>360</b> (10): 1002–14. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMra0804579  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMra0804579'" tppabs="https://doi.org/10.1056%2FNEJMra0804579" class="external text external">10.1056/NEJMra0804579</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19264689  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19264689'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19264689" class="external text external">19264689</a>.</cite></span></li><li id="cite_note-pmid12672069-11"> <span id="mw-reference-text-cite_note-pmid12672069-11" class="mw-reference-text"><cite id="CITEREFKaragiannisWangEastBurke2003" class="citation journal cs1">Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ (April 2003). "Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells". <i>Eur. J. Immunol</i>. <b>33</b> (4): 1030–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Feji.200323185  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Feji.200323185'" tppabs="https://doi.org/10.1002%2Feji.200323185" class="external text external">10.1002/eji.200323185</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12672069  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12672069'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12672069" class="external text external">12672069</a>.</cite></span></li><li id="cite_note-pmid22365654-12"> <span id="mw-reference-text-cite_note-pmid22365654-12" class="mw-reference-text"><cite id="CITEREFBusseBuhlFernandez_VidaurreBlogg2012" class="citation journal cs1">Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J (April 2012). "Omalizumab and the risk of malignancy: results from a pooled analysis". <i>The Journal of Allergy and Clinical Immunology</i>. <b>129</b> (4): 983–9.e6. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2012.01.033  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2012.01.033'" tppabs="https://doi.org/10.1016%2Fj.jaci.2012.01.033" class="external text external">10.1016/j.jaci.2012.01.033</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22365654  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22365654'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22365654" class="external text external">22365654</a>.</cite></span></li><li id="cite_note-pmid10657120-13"> <span id="mw-reference-text-cite_note-pmid10657120-13" class="mw-reference-text"><cite id="CITEREFChang_TW2000" class="citation journal cs1">Chang TW (February 2000). "The pharmacological basis of anti-IgE therapy". <i>Nat. Biotechnol</i>. <b>18</b> (2): 157–62. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F72601  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F72601'" tppabs="https://doi.org/10.1038%2F72601" class="external text external">10.1038/72601</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10657120  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10657120'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10657120" class="external text external">10657120</a>.</cite></span></li><li id="cite_note-pmid16750976-14"> <span id="mw-reference-text-cite_note-pmid16750976-14" class="mw-reference-text"><cite id="CITEREFChangShiung2006" class="citation journal cs1">Chang TW, Shiung YY (June 2006). "Anti-IgE as a mast cell-stabilizing therapeutic agent". <i>The Journal of Allergy and Clinical Immunology</i>. <b>117</b> (6): 1203–12. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2006.04.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2006.04.005'" tppabs="https://doi.org/10.1016%2Fj.jaci.2006.04.005" class="external text external">10.1016/j.jaci.2006.04.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16750976  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16750976'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16750976" class="external text external">16750976</a>.</cite></span></li><li id="cite_note-pmid9013989-15"> <span id="mw-reference-text-cite_note-pmid9013989-15" class="mw-reference-text"><cite id="CITEREFMacGlashanBochnerAdelmanJardieu1997" class="citation journal cs1">MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM (February 1997). "Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody". <i>Journal of Immunology</i>. <b>158</b> (3): 1438–45. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9013989  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9013989'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9013989" class="external text external">9013989</a>.</cite></span></li><li id="cite_note-pmid14657874-16"> <span id="mw-reference-text-cite_note-pmid14657874-16" class="mw-reference-text"><cite id="CITEREFPrussinGriffithBoeselLin2003" class="citation journal cs1">Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB (December 2003). <a href="javascript:if(confirm('https://zenodo.org/record/1259077  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://zenodo.org/record/1259077'" tppabs="https://zenodo.org/record/1259077" class="external text external">"Omalizumab treatment downregulates dendritic cell FcepsilonRI expression"</a>. <i>The Journal of Allergy and Clinical Immunology</i>. <b>112</b> (6): 1147–54. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2003.10.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2003.10.003'" tppabs="https://doi.org/10.1016%2Fj.jaci.2003.10.003" class="external text external">10.1016/j.jaci.2003.10.003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14657874  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14657874'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14657874" class="external text external">14657874</a>.</cite></span></li><li id="cite_note-pmid15748543-17"> <span id="mw-reference-text-cite_note-pmid15748543-17" class="mw-reference-text"><cite id="CITEREFScheinfeld_N2005" class="citation journal cs1">Scheinfeld N (2005). "Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody". <i>Dermatol. Online J</i>. <b>11</b> (1): 2. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15748543  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15748543'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15748543" class="external text external">15748543</a>.</cite></span></li><li id="cite_note-pmid15836747-18"> <span id="mw-reference-text-cite_note-pmid15836747-18" class="mw-reference-text"><cite id="CITEREFHolgateDjukanovićCasaleBousquet2005" class="citation journal cs1">Holgate ST, Djukanović R, Casale T, Bousquet J (April 2005). "Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy". <i>Clin. Exp. Allergy</i>. <b>35</b> (4): 408–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2222.2005.02191.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2222.2005.02191.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2222.2005.02191.x" class="external text external">10.1111/j.1365-2222.2005.02191.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15836747  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15836747'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15836747" class="external text external">15836747</a>.</cite></span></li><li id="cite_note-pmid15753888-19"> <span id="mw-reference-text-cite_note-pmid15753888-19" class="mw-reference-text"><cite id="CITEREFHolgateCasaleWenzelBousquet2005" class="citation journal cs1">Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C (March 2005). "The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation". <i>The Journal of Allergy and Clinical Immunology</i>. <b>115</b> (3): 459–65. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2004.11.053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2004.11.053'" tppabs="https://doi.org/10.1016%2Fj.jaci.2004.11.053" class="external text external">10.1016/j.jaci.2004.11.053</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15753888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15753888'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15753888" class="external text external">15753888</a>.</cite></span></li><li id="cite_note-pmid19839977-20"> <span id="mw-reference-text-cite_note-pmid19839977-20" class="mw-reference-text"><cite id="CITEREFHolgateSmithMassanariJimenez2009" class="citation journal cs1">Holgate S, Smith N, Massanari M, Jimenez P (December 2009). "Effects of omalizumab on markers of inflammation in patients with allergic asthma". <i>Allergy</i>. <b>64</b> (12): 1728–36. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1398-9995.2009.02201.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1398-9995.2009.02201.x'" tppabs="https://doi.org/10.1111%2Fj.1398-9995.2009.02201.x" class="external text external">10.1111/j.1398-9995.2009.02201.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19839977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19839977'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19839977" class="external text external">19839977</a>.</cite></span></li><li id="cite_note-pmid17329558-21"> <span id="mw-reference-text-cite_note-pmid17329558-21" class="mw-reference-text"><cite id="CITEREFvan_der_EntHoekstraRijkers2007" class="citation journal cs1">van der Ent CK, Hoekstra H, Rijkers GT (March 2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117163  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117163'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117163" class="external text external">"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody"</a>. <i>Thorax</i>. <b>62</b> (3): 276–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fthx.2004.035519  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fthx.2004.035519'" tppabs="https://doi.org/10.1136%2Fthx.2004.035519" class="external text external">10.1136/thx.2004.035519</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117163  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117163'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117163" class="external text external">2117163</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17329558  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17329558'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17329558" class="external text external">17329558</a>.</cite></span></li><li id="cite_note-pmid20568389-22"> <span id="mw-reference-text-cite_note-pmid20568389-22" class="mw-reference-text"><cite id="CITEREFKontou-FiliFilisVoulgariPanayiotidis2010" class="citation journal cs1">Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG (June 2010). "Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE". <i>Ann Allergy Asthma Immunol</i>. <b>104</b> (6): 537–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.anai.2010.04.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.anai.2010.04.011'" tppabs="https://doi.org/10.1016%2Fj.anai.2010.04.011" class="external text external">10.1016/j.anai.2010.04.011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20568389  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20568389'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20568389" class="external text external">20568389</a>.</cite></span></li><li id="cite_note-pmid19152970-23"> <span id="mw-reference-text-cite_note-pmid19152970-23" class="mw-reference-text"><cite id="CITEREFFairleyBaumBrandtMessingham2009" class="citation journal cs1">Fairley JA, Baum CL, Brandt DS, Messingham KA (March 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784096  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784096'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784096" class="external text external">"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab"</a>. <i>The Journal of Allergy and Clinical Immunology</i>. <b>123</b> (3): 704–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2008.11.035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2008.11.035'" tppabs="https://doi.org/10.1016%2Fj.jaci.2008.11.035" class="external text external">10.1016/j.jaci.2008.11.035</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784096  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784096'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784096" class="external text external">4784096</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19152970  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19152970'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19152970" class="external text external">19152970</a>.</cite></span></li><li id="cite_note-pmid16771742-24"> <span id="mw-reference-text-cite_note-pmid16771742-24" class="mw-reference-text"><cite id="CITEREFLeeDoggweiler-WiygulKimHill2006" class="citation journal cs1">Lee J, Doggweiler-Wiygul R, Kim S, Hill BD, Yoo TJ (May 2006). "Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE". <i>Int. J. Urol</i>. <b>13</b> (5): 631–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1442-2042.2006.01373.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1442-2042.2006.01373.x'" tppabs="https://doi.org/10.1111%2Fj.1442-2042.2006.01373.x" class="external text external">10.1111/j.1442-2042.2006.01373.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16771742  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16771742'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16771742" class="external text external">16771742</a>.</cite></span></li><li id="cite_note-pmid17931567-25"> <span id="mw-reference-text-cite_note-pmid17931567-25" class="mw-reference-text"><cite id="CITEREFSandsBlumeSchwartz2007" class="citation journal cs1">Sands MF, Blume JW, Schwartz SA (October 2007). "Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab". <i>The Journal of Allergy and Clinical Immunology</i>. <b>120</b> (4): 979–81. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2007.07.041  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2007.07.041'" tppabs="https://doi.org/10.1016%2Fj.jaci.2007.07.041" class="external text external">10.1016/j.jaci.2007.07.041</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17931567  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17931567'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17931567" class="external text external">17931567</a>.</cite></span></li><li id="cite_note-pmid23350994-26"> <span id="mw-reference-text-cite_note-pmid23350994-26" class="mw-reference-text"><cite id="CITEREFde_Llano_LP,_Vennera_Mdel_C,_Álvarez_FJ,_Medina_JF,_Borderías_L,_Pellicer_C,_González_H,_Gullón_JA,_Martínez-Moragón_E,_Sabadell_C,_Zamarro_S,_Picado_C;_Spanish_Registry2013" class="citation journal cs1">de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; Spanish Registry (April 2013). "Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry". <i>J Asthma</i>. <b>50</b> (3): 296–301. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F02770903.2012.757780  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F02770903.2012.757780'" tppabs="https://doi.org/10.3109%2F02770903.2012.757780" class="external text external">10.3109/02770903.2012.757780</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23350994  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23350994'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23350994" class="external text external">23350994</a>.</cite><span class="cs1-maint citation-comment">CS1 maint: multiple names: authors list (link)</span></span></li><li id="cite_note-pmid23709757-27"> <span id="mw-reference-text-cite_note-pmid23709757-27" class="mw-reference-text"><cite id="CITEREFLommatzschKornBuhlVirchow2013" class="citation journal cs1">Lommatzsch M, Korn S, Buhl R, Virchow JC (May 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888607  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888607'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888607" class="external text external">"Against all odds: anti-IgE for intrinsic asthma?"</a>. <i>Thorax</i>. <b>69</b> (1): 94–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fthoraxjnl-2013-203738  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fthoraxjnl-2013-203738'" tppabs="https://doi.org/10.1136%2Fthoraxjnl-2013-203738" class="external text external">10.1136/thoraxjnl-2013-203738</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888607  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888607'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888607" class="external text external">3888607</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23709757  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23709757'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23709757" class="external text external">23709757</a>.</cite></span></li><li id="cite_note-pmid23432142-28"> <span id="mw-reference-text-cite_note-pmid23432142-28" class="mw-reference-text"><cite id="CITEREFMaurerRosénHsiehSaini2013" class="citation journal cs1">Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T (March 2013). <a href="javascript:if(confirm('https://semanticscholar.org/paper/aa57db265c0909d87556810e575a864137ed75f2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/aa57db265c0909d87556810e575a864137ed75f2'" tppabs="https://semanticscholar.org/paper/aa57db265c0909d87556810e575a864137ed75f2" class="external text external">"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria"</a>. <i>N Engl J Med</i>. <b>368</b> (10): 924–35. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa1215372  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa1215372'" tppabs="https://doi.org/10.1056%2FNEJMoa1215372" class="external text external">10.1056/NEJMoa1215372</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23432142  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23432142'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23432142" class="external text external">23432142</a>.</cite></span></li><li id="cite_note-pmid23810097-29"> <span id="mw-reference-text-cite_note-pmid23810097-29" class="mw-reference-text"><cite id="CITEREFKaplanLedfordAshbyCanvin2013" class="citation journal cs1">Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosén K (July 2013). "Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy". <i>The Journal of Allergy and Clinical Immunology</i>. <b>132</b> (1): 101–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaci.2013.05.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaci.2013.05.013'" tppabs="https://doi.org/10.1016%2Fj.jaci.2013.05.013" class="external text external">10.1016/j.jaci.2013.05.013</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23810097  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23810097'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23810097" class="external text external">23810097</a>.</cite></span></li><li id="cite_note-pmid21713650-30"> <span id="mw-reference-text-cite_note-pmid21713650-30" class="mw-reference-text"><cite id="CITEREFKashiwakuraOtaniKawakami2011" class="citation book cs1">Kashiwakura J, Otani IM, Kawakami T (2011). <i>Monomeric IgE and mast cell development, survival and function</i>. <i>Adv Exp Med Biol</i>. Advances in Experimental Medicine and Biology. <b>716</b>. pp.<span>&nbsp;</span>29–46. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-1-4419-9533-9_3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-1-4419-9533-9_3'" tppabs="https://doi.org/10.1007%2F978-1-4419-9533-9_3" class="external text external">10.1007/978-1-4419-9533-9_3</a>. ISBN<span>&nbsp;</span><bdi>978-1-4419-9532-2</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21713650  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21713650'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21713650" class="external text external">21713650</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120126114542/http://www.ville-huningue.fr/fr/entreprises-industries-huningue-haut-rhin-68/novartis-biotechnologie.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120126114542/http://www.ville-huningue.fr/fr/entreprises-industries-huningue-haut-rhin-68/novartis-biotechnologie.html'" tppabs="https://web.archive.org/web/20120126114542/http://www.ville-huningue.fr/fr/entreprises-industries-huningue-haut-rhin-68/novartis-biotechnologie.html" class="external text external">"Archived copy"</a>. Archived from <a href="javascript:if(confirm('http://www.ville-huningue.fr/fr/entreprises-industries-huningue-haut-rhin-68/novartis-biotechnologie.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ville-huningue.fr/fr/entreprises-industries-huningue-haut-rhin-68/novartis-biotechnologie.html'" tppabs="http://www.ville-huningue.fr/fr/entreprises-industries-huningue-haut-rhin-68/novartis-biotechnologie.html" class="external text external">the original</a> on 2012-01-26<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-07-23</span></span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://ec.europa.eu/health/documents/community-register/html/h319.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ec.europa.eu/health/documents/community-register/html/h319.htm'" tppabs="http://ec.europa.eu/health/documents/community-register/html/h319.htm" class="external text external">"Community register of medicinal products for human use"</a>. <i>ec.europa.eu</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20140420180241/http://ec.europa.eu/health/documents/community-register/html/h319.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140420180241/http://ec.europa.eu/health/documents/community-register/html/h319.htm'" tppabs="https://web.archive.org/web/20140420180241/http://ec.europa.eu/health/documents/community-register/html/h319.htm" class="external text external">Archived</a> from the original on 2014-04-20.</cite></span></li><li id="cite_note-The_Scientist-33"> <span id="mw-reference-text-cite_note-The_Scientist-33" class="mw-reference-text">Twombly R. Couple Lead Quest for New Allergy Drug. <i>The Scientist</i> January 7, 1991. <a href="javascript:if(confirm('http://www.the-scientist.com/?articles.view/articleNo/11548/title/Couple-Lead-Quest-For-New-Allergy-Drug/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.the-scientist.com/?articles.view/articleNo/11548/title/Couple-Lead-Quest-For-New-Allergy-Drug/'" tppabs="http://www.the-scientist.com/?articles.view/articleNo/11548/title/Couple-Lead-Quest-For-New-Allergy-Drug/" class="external free external">http://www.the-scientist.com/?articles.view/articleNo/11548/title/Couple-Lead-Quest-For-New-Allergy-Drug/</a> <a href="javascript:if(confirm('https://web.archive.org/web/20160827002525/http://www.the-scientist.com/?articles.view%2FarticleNo%2F11548%2Ftitle%2FCouple-Lead-Quest-For-New-Allergy-Drug%2F  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160827002525/http://www.the-scientist.com/?articles.view%2FarticleNo%2F11548%2Ftitle%2FCouple-Lead-Quest-For-New-Allergy-Drug%2F'" tppabs="https://web.archive.org/web/20160827002525/http://www.the-scientist.com/?articles.view%2FarticleNo%2F11548%2Ftitle%2FCouple-Lead-Quest-For-New-Allergy-Drug%2F" class="external text external">Archived</a><span> 2016-08-27 at the </span>Wayback Machine.</span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text">Development and Licensing Agreement, between Tanox and Ciba-Geigy 1990. <cite class="citation web cs1"><a href="javascript:if(confirm('http://contracts.onecle.com/tanox/ciba-geigy.rd.1990.05.11.shtml  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://contracts.onecle.com/tanox/ciba-geigy.rd.1990.05.11.shtml'" tppabs="http://contracts.onecle.com/tanox/ciba-geigy.rd.1990.05.11.shtml" class="external text external">"Development and Licensing Agreement - Tanox Biosystems Inc. And Ciba-Geigy Ltd. - Sample Contracts and Business Forms"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20130516131954/http://contracts.onecle.com/tanox/ciba-geigy.rd.1990.05.11.shtml  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130516131954/http://contracts.onecle.com/tanox/ciba-geigy.rd.1990.05.11.shtml'" tppabs="https://web.archive.org/web/20130516131954/http://contracts.onecle.com/tanox/ciba-geigy.rd.1990.05.11.shtml" class="external text external">Archived</a> from the original on 2013-05-16<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-07-04</span></span>.</cite></span></li><li id="cite_note-pmid1369991-35"> <span id="mw-reference-text-cite_note-pmid1369991-35" class="mw-reference-text"><cite id="CITEREFChangDavisSunSun1990" class="citation journal cs1">Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW Jr, Hamilton RG (February 1990). "Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases". <i>Bio/Technology</i>. <b>8</b> (2): 122–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnbt0290-122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnbt0290-122'" tppabs="https://doi.org/10.1038%2Fnbt0290-122" class="external text external">10.1038/nbt0290-122</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1369991  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1369991'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1369991" class="external text external">1369991</a>.</cite></span></li><li id="cite_note-pmid8362344-36"> <span id="mw-reference-text-cite_note-pmid8362344-36" class="mw-reference-text"><cite id="CITEREFDavisGossettPinkstonLiou1993" class="citation journal cs1">Davis FM, Gossett LA, Pinkston KL, Liou RS, Sun LK, Kim YW, Chang NT, Chang TW, Wagner K, Bews J, Brinkmann V, Towbin H, Subramanian N, Heusser C (1993). "Can anti-IgE be used to treat allergy?". <i>Springer Semin. Immunopathol</i>. <b>15</b> (1): 51–73. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF00204626  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF00204626'" tppabs="https://doi.org/10.1007%2FBF00204626" class="external text external">10.1007/BF00204626</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8362344  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8362344'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8362344" class="external text external">8362344</a>.</cite></span></li><li id="cite_note-pmid9062345-37"> <span id="mw-reference-text-cite_note-pmid9062345-37" class="mw-reference-text"><cite id="CITEREFCorneDjukanovicThomasWarner1997" class="citation journal cs1">Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang TW, Holgate S (March 1997). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507895  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507895'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507895" class="external text external">"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics"</a>. <i>J Clin Invest</i>. <b>99</b> (5): 879–87. doi:<a href="javascript:if(confirm('https://doi.org/10.1172%2FJCI119252  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1172%2FJCI119252'" tppabs="https://doi.org/10.1172%2FJCI119252" class="external text external">10.1172/JCI119252</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507895  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507895'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507895" class="external text external">507895</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9062345  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9062345'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9062345" class="external text external">9062345</a>.</cite></span></li><li id="cite_note-pmid9433396-38"> <span id="mw-reference-text-cite_note-pmid9433396-38" class="mw-reference-text"><cite id="CITEREFRacine-PoonBottaChangDavis1997" class="citation journal cs1">Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Staehelin T, van Steijn AM, Frank W (December 1997). "Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis". <i>Clin Pharmacol Ther</i>. <b>62</b> (6): 675–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0009-9236%2897%2990087-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0009-9236%2897%2990087-4'" tppabs="https://doi.org/10.1016%2FS0009-9236%2897%2990087-4" class="external text external">10.1016/S0009-9236(97)90087-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9433396  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9433396'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9433396" class="external text external">9433396</a>.</cite></span></li><li id="cite_note-pmid8360482-39"> <span id="mw-reference-text-cite_note-pmid8360482-39" class="mw-reference-text"><cite id="CITEREFPrestaLahrShieldsPorter1993" class="citation journal cs1">Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (September 1993). "Humanization of an antibody directed against IgE". <i>Journal of Immunology</i>. <b>151</b> (5): 2623–32. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8360482  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8360482'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8360482" class="external text external">8360482</a>.</cite></span></li><li id="cite_note-Drug_War-40"> <span id="mw-reference-text-cite_note-Drug_War-40" class="mw-reference-text">Thorpe H. Drug war. (small drug firm Tanox takes on Genentech over patent rights) <i>Texas Monthly,</i> April 1, 1995. <cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20131029193124/http://business.highbeam.com/410545/article-1G1-16816180/drug-war  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131029193124/http://business.highbeam.com/410545/article-1G1-16816180/drug-war'" tppabs="https://web.archive.org/web/20131029193124/http://business.highbeam.com/410545/article-1G1-16816180/drug-war" class="external text external">"About Questia <span>|</span> Questia, Your Online Research Library"</a>. Archived from <a href="javascript:if(confirm('http://business.highbeam.com/410545/article-1G1-16816180/drug-war  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://business.highbeam.com/410545/article-1G1-16816180/drug-war'" tppabs="http://business.highbeam.com/410545/article-1G1-16816180/drug-war" class="external text external">the original</a> on 2013-10-29<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-07-04</span></span>.</cite></span></li><li id="cite_note-anti-IgE_patents-41"> <span id="mw-reference-text-cite_note-anti-IgE_patents-41" class="mw-reference-text">The family of anti-IgE patents. <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.google.com/patents/US5422258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.google.com/patents/US5422258'" tppabs="http://www.google.com/patents/US5422258" class="external text external">"Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20140319212047/http://www.google.com/patents/US5422258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140319212047/http://www.google.com/patents/US5422258'" tppabs="https://web.archive.org/web/20140319212047/http://www.google.com/patents/US5422258" class="external text external">Archived</a> from the original on 2014-03-19<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-09-30</span></span>.</cite>; <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.google.com/patents/US5428133  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.google.com/patents/US5428133'" tppabs="http://www.google.com/patents/US5428133" class="external text external">"Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20140319211751/http://www.google.com/patents/US5428133  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140319211751/http://www.google.com/patents/US5428133'" tppabs="https://web.archive.org/web/20140319211751/http://www.google.com/patents/US5428133" class="external text external">Archived</a> from the original on 2014-03-19<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-06-23</span></span>.</cite>; <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.google.com/patents/US5449760  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.google.com/patents/US5449760'" tppabs="http://www.google.com/patents/US5449760" class="external text external">"Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20140319215356/http://www.google.com/patents/US5449760  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140319215356/http://www.google.com/patents/US5449760'" tppabs="https://web.archive.org/web/20140319215356/http://www.google.com/patents/US5449760" class="external text external">Archived</a> from the original on 2014-03-19<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-09-30</span></span>.</cite>; <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.google.com/patents/US5543144  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.google.com/patents/US5543144'" tppabs="http://www.google.com/patents/US5543144" class="external text external">"Treating hypersensitivities with anti-IGE monoclonal antibodies which bind to IGE-expressing B cells but not basophils"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20140319212303/http://www.google.com/patents/US5543144  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140319212303/http://www.google.com/patents/US5543144'" tppabs="https://web.archive.org/web/20140319212303/http://www.google.com/patents/US5543144" class="external text external">Archived</a> from the original on 2014-03-19<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-06-23</span></span>.</cite>; <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.google.com/patents/US5614611  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.google.com/patents/US5614611'" tppabs="http://www.google.com/patents/US5614611" class="external text external">"Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20140221070331/http://www.google.com/patents/US5614611  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140221070331/http://www.google.com/patents/US5614611'" tppabs="https://web.archive.org/web/20140221070331/http://www.google.com/patents/US5614611" class="external text external">Archived</a> from the original on 2014-02-21<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-06-23</span></span>.</cite>.</span></li><li id="cite_note-Tripartite_Agreement-42"> <span id="mw-reference-text-cite_note-Tripartite_Agreement-42" class="mw-reference-text">Tripartite Cooperation Agreement, by and between NOVARTIS PHARMA AG, GENENTECH, INC, AND TANOX, INC. <cite class="citation web cs1"><a href="javascript:if(confirm('https://www.sec.gov/Archives/edgar/data/1099414/000119312504083427/dex101.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sec.gov/Archives/edgar/data/1099414/000119312504083427/dex101.htm'" tppabs="https://www.sec.gov/Archives/edgar/data/1099414/000119312504083427/dex101.htm" class="external text external">"Tripartite Cooperation Agreement"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160822062214/https://www.sec.gov/Archives/edgar/data/1099414/000119312504083427/dex101.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160822062214/https://www.sec.gov/Archives/edgar/data/1099414/000119312504083427/dex101.htm'" tppabs="https://web.archive.org/web/20160822062214/https://www.sec.gov/Archives/edgar/data/1099414/000119312504083427/dex101.htm" class="external text external">Archived</a> from the original on 2016-08-22<span class="reference-accessdate">. Retrieved <span class="nowrap">2017-09-07</span></span>.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.gene.com/media/press-releases/10167/2006-11-09/genentech-announces-agreement-to-acquire  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gene.com/media/press-releases/10167/2006-11-09/genentech-announces-agreement-to-acquire'" tppabs="http://www.gene.com/media/press-releases/10167/2006-11-09/genentech-announces-agreement-to-acquire" class="external text external">"Genentech: Press Releases - Genentech Announces Agreement to Acquire Tanox for $20 Per Share"</a>. <i>www.gene.com</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20130706045246/http://www.gene.com/media/press-releases/10167/2006-11-09/genentech-announces-agreement-to-acquire  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130706045246/http://www.gene.com/media/press-releases/10167/2006-11-09/genentech-announces-agreement-to-acquire'" tppabs="https://web.archive.org/web/20130706045246/http://www.gene.com/media/press-releases/10167/2006-11-09/genentech-announces-agreement-to-acquire" class="external text external">Archived</a> from the original on 2013-07-06.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.sfgate.com/business/article/Genentech-completes-acquisition-919-million-3656397.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.sfgate.com/business/article/Genentech-completes-acquisition-919-million-3656397.php'" tppabs="http://www.sfgate.com/business/article/Genentech-completes-acquisition-919-million-3656397.php" class="external text external">"Genentech completes acquisition / $919 million for Tanox is its first purchase ever"</a>. 2007-08-03. <a href="javascript:if(confirm('https://web.archive.org/web/20160414133905/http://www.sfgate.com/business/article/Genentech-completes-acquisition-919-million-3656397.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160414133905/http://www.sfgate.com/business/article/Genentech-completes-acquisition-919-million-3656397.php'" tppabs="https://web.archive.org/web/20160414133905/http://www.sfgate.com/business/article/Genentech-completes-acquisition-919-million-3656397.php" class="external text external">Archived</a> from the original on 2016-04-14.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.bbc.co.uk/news/uk-10948091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bbc.co.uk/news/uk-10948091'" tppabs="https://www.bbc.co.uk/news/uk-10948091" class="external text external">"Asthma drug ruling 'nonsensical<span class="cs1-kern-right">'</span>"</a>. <i>BBC News</i>. August 12, 2010. <a href="javascript:if(confirm('https://web.archive.org/web/20100812034009/http://www.bbc.co.uk/news/uk-10948091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100812034009/http://www.bbc.co.uk/news/uk-10948091'" tppabs="https://web.archive.org/web/20100812034009/http://www.bbc.co.uk/news/uk-10948091" class="external text external">Archived</a> from the original on August 12, 2010.</cite></span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text">NICE says yes to treatment for asthma in final draft guidance. <i>NICE</i> March 7, 2013. <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nice.org.uk/newsroom/pressreleases/OmalizumabForAsthmaFAD.jsp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nice.org.uk/newsroom/pressreleases/OmalizumabForAsthmaFAD.jsp'" tppabs="http://www.nice.org.uk/newsroom/pressreleases/OmalizumabForAsthmaFAD.jsp" class="external text external">"News"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20130312202003/http://www.nice.org.uk/newsroom/pressreleases/OmalizumabForAsthmaFAD.jsp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130312202003/http://www.nice.org.uk/newsroom/pressreleases/OmalizumabForAsthmaFAD.jsp'" tppabs="https://web.archive.org/web/20130312202003/http://www.nice.org.uk/newsroom/pressreleases/OmalizumabForAsthmaFAD.jsp" class="external text external">Archived</a> from the original on 2013-03-12<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-07-07</span></span>.</cite></span></li><li id="cite_note-fraud-47"> <span id="mw-reference-text-cite_note-fraud-47" class="mw-reference-text"><cite id="CITEREFSheldon2013" class="citation journal cs1">Sheldon, T (23 August 2013). "Senior Dutch researcher sacked for manipulating data in rheumatoid arthritis drug trial". <i>BMJ (Clinical Research Ed.)</i>. <b>347</b>: f5267. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.f5267  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.f5267'" tppabs="https://doi.org/10.1136%2Fbmj.f5267" class="external text external">10.1136/bmj.f5267</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23974641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23974641'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23974641" class="external text external">23974641</a>.</cite></span></li><li id="cite_note-48"> <span id="mw-reference-text-cite_note-48" class="mw-reference-text"><cite id="CITEREFDavydov2005" class="citation journal cs1">Davydov, L (15 January 2005). <a href="javascript:if(confirm('https://www.aafp.org/afp/2005/0115/p341.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.aafp.org/afp/2005/0115/p341.html'" tppabs="https://www.aafp.org/afp/2005/0115/p341.html" class="external text external">"Omalizumab (Xolair) for treatment of asthma"</a>. <i>American Family Physician</i>. <b>71</b> (2): 341–2. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15686303  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15686303'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15686303" class="external text external">15686303</a>.</cite></span></li></ol></div></div>

</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="General_references">General references</h3></summary>
    
<style data-mw-deduplicate="TemplateStyles:r886047268">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class="refbegin reflist   " style="">
<ul><li>Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. Journal of Allergy and Clinical Immunology. 2017 May 1;139(5):1489-95.</li>
<li>Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomised, double-blind, placebo-controlled clinical trials. Journal of Allergy and Clinical Immunology. 2017 May 1;139(5):1678-80.</li></ul>
</div>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><a href="javascript:if(confirm('https://web.archive.org/web/20080407183513/http://www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080407183513/http://www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf'" tppabs="https://web.archive.org/web/20080407183513/http://www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf" class="external text external">FDA</a></li>
<li><a href="javascript:if(confirm('https://www.asthmamatters.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.asthmamatters.com/'" tppabs="https://www.asthmamatters.com/" class="external text external">AsthmaMatters Every Day</a></li>
<li><a href="javascript:if(confirm('http://www.xolair.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.xolair.com/'" tppabs="http://www.xolair.com/" class="external text external">Xolair</a></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_the_immune_system" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="text-align:center;"><div id="Monoclonal_antibodies_for_the_immune_system" style="font-size:114%;margin:0 4em">Monoclonal antibodies for the immune system</div></th></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Immune system</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppression</i>: Abrilumab</li>
<li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Anifrolumab<sup>†</sup></li>
<li>Atorolimumab</li>
<li>Avelumab</li>
<li>Belimumab</li>
<li>Bleselumab</li>
<li>Brodalumab</li>
<li>Camidanlumab tesirine</li>
<li>Carlumab</li>
<li>Cemiplimab</li>
<li>Dupilumab</li>
<li>Eldelumab</li>
<li>Emapalumab<sup>†</sup></li>
<li>Fresolimumab</li>
<li>Golimumab</li>
<li>Ianalumab<sup>†</sup></li>
<li>Lanadelumab</li>
<li>Lenzilumab</li>
<li>Lerdelimumab</li>
<li>Lirilumab</li>
<li>Mavrilimumab</li>
<li>Metelimumab</li>
<li>Morolimumab</li>
<li>Namilumab</li>
<li>Oleclumab</li>
<li>Oxelumab§</li>
<li>Pamrevlumab</li>
<li>Placulumab</li>
<li>Relatlimab<sup>†</sup></li>
<li>Sarilumab</li>
<li>Sifalimumab</li>
<li>Tabalumab</li>
<li>Tezepelumab<sup>†</sup></li>
<li>Ulocuplumab</li>
<li>Varlilumab</li></ul>

<ul><li><i>Immune activation</i>: Ipilimumab</li>
<li>Atezolizumab</li>
<li>Durvalumab</li>
<li>Nivolumab</li>
<li>Pembrolizumab</li>
<li>Tremelimumab<sup>†</sup></li>
<li>Urelumab</li></ul>

<ul><li><i>Other</i>: Bertilimumab</li>
<li>Zanolimumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Afelimomab</li>
<li>Elsilimomab</li>
<li>Faralimomab</li>
<li>Gavilimomab</li>
<li>Inolimomab</li>
<li>Maslimomab</li>
<li>Nerelimomab</li>
<li>Odulimomab</li>
<li>Telimomab aritox</li>
<li>Vepalimomab</li>
<li>Zolimomab aritox</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Andecaliximab<sup>†</sup></li>
<li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li>Clenoliximab</li>
<li>Galiximab</li>
<li>Gomiliximab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Keliximab</li>
<li>Lumiliximab</li>
<li>Priliximab</li>
<li>Teneliximab</li>
<li>Vapaliximab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppressive:</i> Aselizumab</li>
<li>Apolizumab<sup>§</sup></li>
<li>Benralizumab</li>
<li>Camrelizumab<sup>†</sup></li>
<li>Cedelizumab</li>
<li>Certolizumab pegol</li>
<li>Crizanlizumab<sup>†</sup></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Dostarlimab<sup>†</sup></li>
<li>Eculizumab</li>
<li>Efalizumab<sup>‡</sup></li>
<li>Epratuzumab</li>
<li>Erlizumab</li>
<li>Etrolizumab<sup>†</sup></li>
<li>Fontolizumab</li>
<li>Inebilizumab</li>
<li>Itolizumab</li>
<li>Lampalizumab<sup>†</sup></li>
<li>Letolizumab</li>
<li>Ligelizumab<sup>†</sup></li>
<li>Lulizumab pegol</li>
<li>Mepolizumab</li>
<li>Mogamulizumab</li>
<li>Natalizumab</li>
<li>Ocrelizumab</li>
<li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li>
<li>Ozoralizumab</li>
<li>Pascolizumab</li>
<li>Pateclizumab</li>
<li>Pembrolizumab</li>
<li>Pexelizumab</li>
<li>Pidilizumab</li>
<li>Plozalizumab</li>
<li>PRO 140<sup>†</sup></li>
<li>Quilizumab</li>
<li>Ravulizumab</li>
<li>Reslizumab</li>
<li>Rontalizumab</li>
<li>Rovelizumab</li>
<li>Ruplizumab</li>
<li>Samalizumab</li>
<li>Satralizumab</li>
<li>Siplizumab</li>
<li>Spartalizumab<sup>†</sup></li>
<li>Talizumab</li>
<li>Teplizumab</li>
<li>Tislelizumab</li>
<li>Tocilizumab</li>
<li>Toralizumab</li>
<li>Tregalizumab</li>
<li>Vatelizumab</li>
<li>Vedolizumab</li>
<li>Visilizumab</li>
<li>Vobarilizumab</li>
<li>TGN1412<sup>§</sup><br><i>Non-immunosuppressive:</i> Ibalizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric + humanized<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Otelixizumab</li>
<li>Sutimlimab<sup>†</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Interleukin</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bermekimab</li>
<li>Brazikumab</li>
<li>Briakinumab</li>
<li>Canakinumab</li>
<li>Fezakinumab</li>
<li>Fletikumab</li>
<li>Guselkumab</li>
<li>Secukinumab</li>
<li>Sirukumab</li>
<li>Tralokinumab<sup>†</sup></li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anrukinzumab</li>
<li>Bimekizumab<sup>†</sup></li>
<li>Clazakizumab</li>
<li>Gevokizumab</li>
<li>Ixekizumab</li>
<li>Mirikizumab<sup>†</sup></li>
<li>Lebrikizumab</li>
<li>Olokizumab<sup>†</sup></li>
<li>Perakizumab</li>
<li>Risankizumab</li>
<li>Tildrakizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Veterinary</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Lokivetmab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Inflammatory lesions</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Mouse" scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Besilesomab</li>
<li>Fanolesomab<sup>‡</sup></li>
<li>Lemalesomab</li>
<li>Sulesomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="text-align:center;;background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Drugs_for_obstructive_airway_diseases:_asthma/COPD_(R03)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Drugs_for_obstructive_airway_diseases:_asthma/COPD_(R03)" style="font-size:114%;margin:0 4em">Drugs for obstructive airway diseases: asthma/COPD (R03)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Adrenergics, inhalants</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Short-acting <span>β</span><sub>2</sub> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Bitolterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bitolterol" title="Bitolterol">Bitolterol</a></li>
<li>Carbuterol</li>
<li><a href="Fenoterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenoterol" title="Fenoterol">Fenoterol</a></li>
<li><a href="Isoetarine.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoetarine" title="Isoetarine">Isoetarine</a></li>
<li><a href="Pirbuterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Pirbuterol" title="Pirbuterol">Pirbuterol</a></li>
<li><a href="Procaterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Procaterol" title="Procaterol">Procaterol</a></li>
<li>Reproterol</li>
<li>Rimiterol</li>
<li><a href="Salbutamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Salbutamol" title="Salbutamol">Salbutamol (albuterol)</a><sup>#</sup>/Levosalbutamol (levalbuterol)</li>
<li><a href="Terbutaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Terbutaline" title="Terbutaline">Terbutaline</a></li>
<li>Tulobuterol</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Long-acting <span>β</span><sub>2</sub> agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Bambuterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bambuterol" title="Bambuterol">Bambuterol</a></li>
<li><a href="Clenbuterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clenbuterol" title="Clenbuterol">Clenbuterol</a></li>
<li><a href="Formoterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Formoterol" title="Formoterol">Formoterol</a>/<a href="Arformoterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Arformoterol" title="Arformoterol">Arformoterol</a></li>
<li><a href="Salmeterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Salmeterol" title="Salmeterol">Salmeterol</a></li>
<li><span class="new">Salmefamol</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Ultra-long-acting <span>β</span><sub>2</sub> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abediterol</li>
<li>Carmoterol</li>
<li>Indacaterol</li>
<li>Olodaterol</li>
<li>Vilanterol</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Epinephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Epinephrine" title="Epinephrine" class="mw-redirect">Epinephrine</a><sup>#</sup></li>
<li>Hexoprenaline</li>
<li><a href="Isoprenaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoprenaline" title="Isoprenaline">Isoprenaline (isoproterenol)</a></li>
<li><a href="Orciprenaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Orciprenaline" title="Orciprenaline">Orciprenaline (metaproterenol)</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Glucocorticoids</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Beclometasone_dipropionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Beclometasone_dipropionate" title="Beclometasone dipropionate" class="mw-redirect">Beclometasone</a><sup>#</sup></li>
<li><a href="Betamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Betamethasone" title="Betamethasone">Betamethasone</a><sup>#</sup></li>
<li><a href="Budesonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Budesonide" title="Budesonide">Budesonide</a></li>
<li><a href="Ciclesonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclesonide" title="Ciclesonide">Ciclesonide</a></li>
<li><a href="Flunisolide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flunisolide" title="Flunisolide">Flunisolide</a></li>
<li><a href="Fluticasone_propionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluticasone_propionate" title="Fluticasone propionate">Fluticasone propionate</a></li>
<li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone</a></li>
<li><a href="Triamcinolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Triamcinolone" title="Triamcinolone">Triamcinolone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anticholinergics/<br>muscarinic antagonist</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aclidinium bromide</li>
<li>Glycopyrronium bromide</li>
<li><a href="Ipratropium_bromide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ipratropium_bromide" title="Ipratropium bromide">Ipratropium bromide</a><sup>#</sup></li>
<li>Oxitropium bromide</li>
<li><a href="Tiotropium_bromide.htm" tppabs="https://ptable.com/wiki/compounds/A/Tiotropium_bromide" title="Tiotropium bromide">Tiotropium bromide</a></li>
<li>Umeclidinium bromide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mast cell stabilizers</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cromoglicate</li>
<li><a href="Nedocromil.htm" tppabs="https://ptable.com/wiki/compounds/A/Nedocromil" title="Nedocromil">Nedocromil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Xanthine.htm" tppabs="https://ptable.com/wiki/compounds/A/Xanthine" title="Xanthine">Xanthines</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Acefylline</li>
<li>Ambuphylline</li>
<li>Bamifylline</li>
<li>Doxofylline</li>
<li><a href="Enprofylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Enprofylline" title="Enprofylline">Enprofylline</a></li>
<li>Etamiphylline</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Proxyphylline  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Proxyphylline'" tppabs="https://ptable.com/wiki/compounds/A/Proxyphylline" title="Proxyphylline">Proxyphylline</a></li>
<li><a href="Theophylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Theophylline" title="Theophylline">Theophylline</a>/<a href="Aminophylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminophylline" title="Aminophylline">Aminophylline</a>/<a href="Choline_theophyllinate.htm" tppabs="https://ptable.com/wiki/compounds/A/Choline_theophyllinate" title="Choline theophyllinate">Choline theophyllinate</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Eicosanoid inhibition</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Leukotriene antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Montelukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Montelukast" title="Montelukast">Montelukast</a></li>
<li><a href="Pranlukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Pranlukast" title="Pranlukast">Pranlukast</a></li>
<li><a href="Zafirlukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Zafirlukast" title="Zafirlukast">Zafirlukast</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Arachidonate 5-lipoxygenase inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Zileuton.htm" tppabs="https://ptable.com/wiki/compounds/A/Zileuton" title="Zileuton">Zileuton</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thromboxane receptor antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Ramatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramatroban" title="Ramatroban">Ramatroban</a></li>
<li>Seratrodast</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-xanthine PDE4 inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Ibudilast.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibudilast" title="Ibudilast">Ibudilast</a></li>
<li>Roflumilast</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others/unknown</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amlexanox.htm" tppabs="https://ptable.com/wiki/compounds/A/Amlexanox" title="Amlexanox">Amlexanox</a></li>
<li>Eprozinol</li>
<li>Fenspiride</li>
<li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combination products</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aclidinium bromide/formoterol</li>
<li>Beclometasone/formoterol</li>
<li>Beclometasone/formoterol/glycopyrronium bromide</li>
<li>Budesonide/formoterol</li>
<li>Fluticasone furoate/umeclidinium bromide/vilanterol</li>
<li>Fluticasone furoate/vilanterol</li>
<li>Fluticasone propionate/salmeterol</li>
<li>Glycopyrronium bromide/formoterol</li>
<li>Indacaterol/glycopyrronium bromide</li>
<li>Indacaterol/glycopyrronium bromide/mometasone</li>
<li>Indacaterol/mometasone</li>
<li>Ipratropium bromide/salbutamol</li>
<li>Mometasone/formoterol</li>
<li>Umeclidinium bromide/vilanterol</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div><span>
</span>





<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>